Pune-based Serum Institute of India (SII) got an approval from the Drugs Controller General of India (DCGI) to resume the trials of the Oxford-AstraZeneca COVID-19 vaccine.
A few days ago, Oxford University put a temporary halt on the vaccine trials due to a suspected case of adverse reaction in one of the participants of the clinical trials. However, on 12th September, according to a report released by AstraZeneca, the Medicines Health Regulatory Authority (MHRA) permitted the resumption of the vaccine trials stating that it was ‘safe to do so’.
Following this, SII also received approval to resume the trial of the vaccine known as Covishield in India. Adar Poonawalla, CEO of SII, tweeted:
As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford. https://t.co/ThIU2ELkO3
— Adar Poonawalla (@adarpoonawalla) September 12, 2020
Despite the delay, AstraZeneca stated the vaccine is expected to be available by the end of the year or by early next year. Notably, these delays are a fairly common phenomenon in vaccine trials. Health Minister of UK, Matt Hancock, stated:
Vaccine Candidate COVAXIN Produces Robust Immune Response In Monkeys
Recently, Bharat Biotech published the results of COVAXIN’s animal trials. The results indicated a decline in the viral replication in the nasal cavity, throat and lung tissues of monkeys.
Bharat Biotech proudly announces the animal study results of COVAXIN™ – These results demonstrate the protective efficacy in a live viral challenge model.
— BharatBiotech (@BharatBiotech) September 11, 2020
In the trials, 20 rhesus macaques (equally split into four groups) were given the vaccine. Amongst these groups, one group was given a placebo while the other three were given three separate vaccines. Talking about the results, Bharath Biotech stated:
COVAXIN and Covishield are among the top vaccine candidates to save us from the clutches of the deadly virus.